Condition (MeSH)
Coronary Restenosis
ClinicalTrials.gov lists 106 trials for Coronary Restenosis or a narrower condition beneath it. Abbott Medical Devices has the most among industry and government lead sponsors, with 39.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
106 of the 106 trials are tagged with Coronary Restenosis itself; the rest are tagged with a narrower condition beneath it.
When did Coronary Restenosis trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 3 |
| 2016 | 2 |
| 2015 | 3 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Coronary Restenosis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 4 |
| Phase 2 | 4 |
| Phase 2/3 | 4 |
| Phase 3 | 9 |
| Phase 4 | 20 |
| Not applicable | 31 |
| Observational | 34 |
How many Coronary Restenosis trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Active, not recruiting | 2 |
| Completed | 74 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Coronary Restenosis trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Abbott Medical Devices | 39 |
| Biosensors Europe SA | 2 |
| Biotronik AG | 2 |
| North Texas Veterans Healthcare System | 2 |
| Aziende Chimiche Riunite Angelini Francesco S.p.A | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Coronary Restenosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sirolimus | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ORSIRO | 2 |
| Immunosuppressive Therapy | 2 |
| Secondary prevention for atherosclerotic coronary artery disease | 2 |
| Supportive therapies | 2 |
| clopidogrel + aspirin OR prasugrel + aspirin | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Coronary Restenosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Others/Miscellaneous | 2,099 | 1 |
| Angina pectoris | 2,080 | 12 |
| ANGINA PECTORIS | 708 | 7 |
| Non-cardiac chest pain | 542 | 8 |
| Angina unstable | 396 | 10 |
Showing 5 of 10 adverse events.
Which publications cover Coronary Restenosis? (860)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. | Journal of the American Heart Association | 2026 | Yes |
| First-in-man study of a novel everolimus-coated balloon for the treatment of coronary in-stent restenosis. | Coronary artery disease | 2025 | Yes |
| Optical coherence tomography versus angiography to guide percutaneous coronary intervention in patients with in-stent restenosis: an observational study. | Coronary artery disease | 2025 | Yes |
| Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease. | American heart journal | 2025 | Yes |
| Randomized Trial of Biolimus DCB for In-Stent Restenosis: The Primary Results of the REFORM Study. | JACC. Cardiovascular interventions | 2025 | Yes |
Showing 5 of 860 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.